A lunchtime seminar entitled The Future of Pharma by Professor Brian D Smith was hosted by solicitors Matthew Arnold and Baldwin LLP in conjunction with Watford Chamber of Commerce.Professor Smith, a recognised leader in the pharmaceutical field, explored the rapid changes and challenges facing the pharma industry.He discussed how companies have to recognise that change is needed and what action is required if they are to remain successful.He said: “Evolution is what is happening to the pharmaceutical industry. It is not a metaphor, it is a fact.”He went on to say that for the industry to survive, pharmaceutical firms needed to keep adapting.He argued that one way to do this was to have some understanding of what to expect in the future and he provided some of his own predictions on what the future would hold.Pharmaceutical companies form a considerable hub in the Watford area and more than 30 companies attended the event, including large firms such as Pfizer and AstraZeneca. The audience totalled more than 100 people.Paul Gershlick, head of pharmaceuticals and life sciences at MAB, said: “We were delighted Professor Smith was able to come and that so many of the local pharma businesses were in attendance.“His talk was engaging and provided a real insight to the future of the industry. There is now a substantial hub in the Watford area which continues to provide growth and development both to the local area and the pharmaceutical industry.”Sanjay Purohit, from Watford and West Herts Chamber of Commerce added: “We are delighted to have been involved in delivering this very successful, sector focused event. It is one of a series we have planned for 2012, to enable growth, business support and the economic vibrancy of Watford, in challenging times.“The event also supports the Watford Health Campus Project, ensuring pharmaceutical and life science companies that attended are aware of this substantial opportunity to them.”
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment